Drug Trial Radar · NCT03443869
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
601
Actual
Start
May 3, 2018
Primary completion
Apr 5, 2022
Study completion Apr 5, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks post-transplant.
Conditions
- CMV Disease
Interventions
LetermovirDrug
LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
ValganciclovirDrug
900 mg VGCV tablet orally, once daily for 28 weeks
Acyclovir (ACV)Drug
400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
Placebo to ACVDrug
Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
Placebo to LETDrug
Placebo to LET tablet orally, once daily for 28 weeks
Placebo to VGCVDrug
Placebo to VGCV tablet orally, once daily for 28 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplantTime frame: Up to 52 weeks
Locations
94 sites in 16 countries. Site status is shown where the registry gives one.
UAB ( Site 0269)
Birmingham, Alabama
UCLA Medical Center ( Site 0266)
Los Angeles, California
UC Davis Medical Center ( Site 0271)
Sacramento, California
University of California-San Francisco ( Site 0236)
San Francisco, California
Stanford Health Care ( Site 0235)
Stanford, California
The Emory Clinic ( Site 0247)
Atlanta, Georgia
University of Chicago ( Site 0251)
Chicago, Illinois
Indiana University ( Site 0261)
Indianapolis, Indiana
Ochsner Clinic Foundation ( Site 0238)
New Orleans, Louisiana
University of Maryland Medical Center ( Site 0234)
Baltimore, Maryland
Johns Hopkins Hospital ( Site 0232)
Baltimore, Maryland
Brigham & Women's Hospital ( Site 0244)
Boston, Massachusetts
Henry Ford Hospital ( Site 0242)
Detroit, Michigan
University of Nebraska Medical Center ( Site 0272)
Omaha, Nebraska
Saint Barnabas Medical Center ( Site 0250)
Livingston, New Jersey
Icahn School of Medicine at Mount Sinai ( Site 0256)
New York, New York
Columbia University Medical Center ( Site 0255)
New York, New York
New York Presbyterian Hospital - Weill Cornell Medical Center ( Site 0276)
New York, New York
Duke University Medical Center ( Site 0243)
Durham, North Carolina
Wake Forest University Baptist Medical Center ( Site 0260)
Winston-Salem, North Carolina
The Ohio State University Wexner Medical Center ( Site 0264)
Columbus, Ohio
University of Pennsylvania ( Site 0270)
Philadelphia, Pennsylvania
University of Pittsburgh ( Site 0252)
Pittsburgh, Pennsylvania
Medical University of South Carolina ( Site 0257)
Charleston, South Carolina
Vanderbilt University Medical Center ( Site 0275)
Nashville, Tennessee
Virginia Commonwealth University ( Site 0245)
Richmond, Virginia
University of Washington Medical Center ( Site 0246)
Seattle, Washington
Instituto de Nefrologia Nephrology S.A. ( Site 0182)
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires ( Site 0188)
CABA, Argentina
Instituto de Cardiología de Corrientes Juana F. Cabral ( Site 0181)
Corrientes, Argentina
Clinica de nefrologia urologia y enfermedades cardiovasculares ( Site 0354)
Santa Fe, Argentina
Hospital El Cruce Nestor Carlos Kirchner ( Site 0351)
San Juan Bautista, Buenos Aires, Argentina
CEMIC ( Site 0352)
Buenos Aires, Buenos Aires F.D., Argentina
Royal Prince Alfred Hospital ( Site 0005)
Camperdown, New South Wales, Australia
Westmead Hospital ( Site 0006)
Westmead, New South Wales, Australia
Princess Alexandra Hospital ( Site 0004)
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital ( Site 0003)
Adelaide, South Australia, Australia
Monash Health-Monash Medical Centre ( Site 0008)
Clayton, Victoria, Australia
Royal Melbourne Hospital ( Site 0007)
Parkville, Victoria, Australia
Allgemeines Krankenhaus Universitaetskliniken Wien ( Site 0032)
Vienna, Austria
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.